BR112019002689A2 - terapia com rapamicina tópica - Google Patents
terapia com rapamicina tópicaInfo
- Publication number
- BR112019002689A2 BR112019002689A2 BR112019002689A BR112019002689A BR112019002689A2 BR 112019002689 A2 BR112019002689 A2 BR 112019002689A2 BR 112019002689 A BR112019002689 A BR 112019002689A BR 112019002689 A BR112019002689 A BR 112019002689A BR 112019002689 A2 BR112019002689 A2 BR 112019002689A2
- Authority
- BR
- Brazil
- Prior art keywords
- rapamycin
- conditions
- topical rapamycin
- rapamycin therapy
- therapy
- Prior art date
Links
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title abstract 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title abstract 3
- 229960002930 sirolimus Drugs 0.000 title abstract 3
- 230000000699 topical effect Effects 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 208000003120 Angiofibroma Diseases 0.000 abstract 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 abstract 1
- 210000004927 skin cell Anatomy 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662372940P | 2016-08-10 | 2016-08-10 | |
| PCT/US2017/046320 WO2018031789A1 (en) | 2016-08-10 | 2017-08-10 | Topical rapamycin therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019002689A2 true BR112019002689A2 (pt) | 2019-05-14 |
Family
ID=59684091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019002689A BR112019002689A2 (pt) | 2016-08-10 | 2017-08-10 | terapia com rapamicina tópica |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20190167649A1 (enExample) |
| EP (1) | EP3496712A1 (enExample) |
| JP (1) | JP2019527711A (enExample) |
| KR (1) | KR20190039220A (enExample) |
| CN (1) | CN109689053A (enExample) |
| AU (1) | AU2017311491A1 (enExample) |
| BR (1) | BR112019002689A2 (enExample) |
| CA (1) | CA3032473A1 (enExample) |
| MX (1) | MX2019001670A (enExample) |
| RU (1) | RU2019106483A (enExample) |
| WO (1) | WO2018031789A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3049402A1 (en) | 2017-01-06 | 2018-07-12 | Palvella Therapeutics Llc | Anhydrous compositions of mtor inhibitors and methods of use |
| US12109199B2 (en) | 2018-02-06 | 2024-10-08 | Georgetown University | Topical mTOR inhibitors for cutaneous proliferative and vascular conditions |
| US11000513B2 (en) | 2018-07-02 | 2021-05-11 | Palvella Therapeutics, Inc. | Anhydrous compositions of mTOR inhibitors and methods of use |
| JP2022511270A (ja) * | 2018-08-30 | 2022-01-31 | ケミストリーアールエックス． | シロリムス含有組成物 |
| CN109431997B (zh) * | 2018-12-20 | 2021-06-04 | 武汉科福新药有限责任公司 | 一种雷帕霉素局部注射制剂及其制备方法 |
| EP3927319A1 (en) | 2019-02-20 | 2021-12-29 | AI Therapeutics, Inc. | Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders |
| US20220142990A1 (en) * | 2019-02-27 | 2022-05-12 | Osaka University | External preparation for treating a vascular anomaly |
| AU2021211317A1 (en) * | 2020-01-24 | 2022-09-01 | Nobelpharma Co., Ltd. | External preparation containing rapamycin |
| AU2020277132B1 (en) * | 2020-11-24 | 2021-11-04 | Aft Pharmaceuticals Limited | A Rapamycin Composition |
| AU2023203871B1 (en) * | 2023-06-20 | 2024-07-25 | Aft Pharmaceuticals Ltd | A Rapamycin Method of Treatment and Composition |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9606452D0 (en) | 1996-03-27 | 1996-06-05 | Sandoz Ltd | Organic compounds |
| AU735648B2 (en) | 1996-07-12 | 2001-07-12 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
| GB9723669D0 (en) | 1997-11-07 | 1998-01-07 | Univ Aberdeen | Skin penetration enhancing components |
| CN100374158C (zh) | 2002-08-12 | 2008-03-12 | 密执安州立大学董事会 | 降低细胞atp水平的药剂在制备药物中的应用 |
| RU2007130406A (ru) | 2005-03-02 | 2009-04-10 | Вайет (Us) | Очистка рапамицина |
| PT1983984T (pt) | 2006-02-02 | 2018-06-14 | Novartis Ag | Tratamento da esclerosa tuberosa |
| US20120022095A1 (en) | 2010-06-24 | 2012-01-26 | Teng Joyce M C | Topical rapamycin for treatment of facial angiofibromas in tuberous sclerosis |
| US20130102572A1 (en) * | 2011-04-12 | 2013-04-25 | Dow Pharmaceutical Sciences | Methods of treating skin conditions exhibiting telangiectasia |
| WO2014117035A1 (en) * | 2013-01-24 | 2014-07-31 | Transderm, Inc. | COMPOSITIONS FOR TRANSDERMAL DELIVERY OF mTOR INHIBITORS |
| HUP1400075A2 (hu) * | 2014-02-14 | 2015-08-28 | Druggability Technologies Ip Holdco Jersey Ltd | Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói |
| US10695326B2 (en) * | 2015-09-24 | 2020-06-30 | Drexel University | Compositions and methods for treating or preventing dermal disorders |
| CN105663027B (zh) * | 2016-04-01 | 2018-12-18 | 中国人民解放军广州军区武汉总医院 | 西罗莫司外用制剂、其制备方法及用途 |
-
2017
- 2017-08-10 US US16/324,274 patent/US20190167649A1/en not_active Abandoned
- 2017-08-10 RU RU2019106483A patent/RU2019106483A/ru unknown
- 2017-08-10 KR KR1020197006896A patent/KR20190039220A/ko not_active Ceased
- 2017-08-10 MX MX2019001670A patent/MX2019001670A/es unknown
- 2017-08-10 BR BR112019002689A patent/BR112019002689A2/pt not_active IP Right Cessation
- 2017-08-10 AU AU2017311491A patent/AU2017311491A1/en not_active Abandoned
- 2017-08-10 CN CN201780049324.6A patent/CN109689053A/zh active Pending
- 2017-08-10 WO PCT/US2017/046320 patent/WO2018031789A1/en not_active Ceased
- 2017-08-10 CA CA3032473A patent/CA3032473A1/en not_active Abandoned
- 2017-08-10 JP JP2019506721A patent/JP2019527711A/ja active Pending
- 2017-08-10 EP EP17755383.1A patent/EP3496712A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019106483A3 (enExample) | 2020-12-04 |
| MX2019001670A (es) | 2019-07-04 |
| AU2017311491A1 (en) | 2019-02-07 |
| KR20190039220A (ko) | 2019-04-10 |
| RU2019106483A (ru) | 2020-09-11 |
| US20190167649A1 (en) | 2019-06-06 |
| EP3496712A1 (en) | 2019-06-19 |
| WO2018031789A1 (en) | 2018-02-15 |
| JP2019527711A (ja) | 2019-10-03 |
| CN109689053A (zh) | 2019-04-26 |
| CA3032473A1 (en) | 2018-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019002689A2 (pt) | terapia com rapamicina tópica | |
| CY1123459T1 (el) | Χρηση των κανναβινοειδων στη θεραπεια του συμπλεγματος οζωδους σκληρυνσης | |
| BR112015023203A2 (pt) | métodos para tratamento de câncer, para aumentar a eficiência de um tratamento de câncer, para retardar e/ou prevenir o desenvolvimento de câncer, para tratar um indivíduo com câncer, para aumentar a sensibilidade para um agente de terapia para câncer, para estender um período de sensibilidade e para estender a duração da resposta para uma terapia para câncer, e usos | |
| CO2017001994A2 (es) | Compuestos activos hacia bromodominios | |
| CR20170014A (es) | Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer | |
| UY37435A (es) | Pirrolidinas sustituidas y métodos para usarlas | |
| BR112018067368A2 (pt) | terapia de combinação com anticorpos anti-cd73 | |
| MX393974B (es) | Terapia de combinacion para tratamiento de cancer. | |
| BR112017006113A8 (pt) | usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits. | |
| CL2016000298A1 (es) | Compuestos derivados de tieno[2,3-c]piran con actividad moduladora del regulador de la conductancia transmembrana de la fibrosis quistica (cftr); composicion farmaceutica que los comprende; utiles en el tratamiento de la fibrosis quistica. | |
| EP3735976A3 (en) | Therapeutic use of mitochondria and combined mitochondrial agents | |
| MX387788B (es) | Uso de agentes activos durante tratamientos quimicos. | |
| CL2016002312A1 (es) | Modulador del receptor de andrógeno y usos de este. | |
| BR112015009189A2 (pt) | conjunto de potência para um autoinjetor e autoinjetor que contém o mesmo | |
| MX2020003959A (es) | Metodos terapeuticos relacionados con los inhibidores de hsp90. | |
| BR112019005139A2 (pt) | anticorpos anti-il-33 e usos dos mesmos | |
| BR112018008882A8 (pt) | método para tratar um distúrbio proliferativo e produto farmacêutico | |
| BR112017005598A2 (pt) | macrociclos peptidomiméticos e usos dos mesmos | |
| BR112018073518A2 (pt) | métodos para sensibilização de células de câncer a um tratamento anticâncer, para potencialização do efeito terapêutico de um tratamento anticâncer e para tratamento de câncer, composição, modulador de canais de ânion regulados por volume, kit de peças, e, uso de um modulador de canais de ânion regulados por volume | |
| BR112017009584A2 (pt) | tratamento de retinite pigmentosa com n-acetilcisteína amida | |
| WO2016160621A3 (en) | Nk-92 cells in combination therapy with cancer drugs | |
| BR112019024566A2 (pt) | inibidores de pirazol magl | |
| AU2016206832A8 (en) | Non-invasive systems and methods for treatment of a host carrying a virus with photoactivatable drugs | |
| BR112018001435A2 (pt) | métodos para entrega linfática de agentes ativos | |
| BR112019005040A2 (pt) | aplicação de pridopidina para tratamento de síndrome de rett |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2735 DE 06-06-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |